Release No 14/2010 Affitech Change in Ownership Copenhagen and Oslo, April 27, 2010 Affitech A/S, (NASDAQ OMX: AFFI), the antibody medicines company, today announced that Arendals Fossekompani ASA, a shareholder in Affitech, has informed the Company that the 28,315,035 shares owned by Arendals Fossekompani ASA, each of nominal value DKK 0.50 representing 28,315,035 voting rights, now represent 5.81% of the outstanding share capital of the Company. The company has one share class. For more information please contact: Affitech A/S: Dr Robert Burns, Chief Executive Officer Tel # +45 50 99 76 42 Randi Krogsgaard, Corporate Communications Tel # +45 2320 1001 About Affitech Affitech AS is a publicly traded (NASDAG OMX Copenhagen) human therapeutic antibody company headquartered in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech's premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company's proprietary product candidates were generated by CBAS™. Further information is available at www.affitech.com. Disclaimer This news release contains forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on results of the financial condition and operations of Affitech A/S. There are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forecasts. These factors include, among other things, risks associated with technological development, the risk that research & development will not yield new products that achieve commercial success, the impact of competition, the ability to transact viable and profitable commercial deals, the risk of non-approval of patents not yet granted, and difficulties of obtaining relevant governmental approvals for new products. No expressed or implied representations or warranties are given concerning Affitech A/S or the accuracy or completeness of the information provided herein, and no claims shall be made by the recipient of this news release by virtue of the information contained herein.